|Dr. Josep Bassaganya-Riera DVM, Ph.D.||Chairman, Pres & CEO||741.77k||N/A||1975|
|Ms. Jyoti Chauhan M.S.||Exec. VP of Operations & Regulatory Affairs||281.42k||N/A||1989|
|Dr. Raquel Hontecillas DVM, Ph.D.||Chief Scientific Officer||228.76k||N/A||1972|
|Ms. Jennifer Collette CPA||VP of Fin. & Controller||N/A||N/A||N/A|
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Landos Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.